secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rallybio Corp (RLYB)
CIK:        0001739410
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001739410-24-000132
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rallybio Q3 net loss narrows to $11.5M; RLYB212 Phase 2 to screen in Q4
-----------------------------------------------------------------------

- Net loss $11.5M ($0.26/share) vs $18.4M ($0.45) in Q3 2023; revenue $0.3M from J&J collaboration.
- Cash $75.1M as of Sep 30, 2024 provides runway into mid-2026; R&D expenses down 38% to $8.2M.
- RLYB212 Phase 2 CTA approved by EMA and MHRA; screening for pregnant women at FNAIT risk to start Q4 2024.
- RLYB116 manufacturing improvements completed; biomarker data suggests potential in PNH and APS beyond myasthenia gravis.
- ENPP1 inhibitor candidate nomination with Exscientia on track for Dec 2024; preclinical data showed PPi reduction and improved bone mineralization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739410/000173941024000132/0001739410-24-000132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739410/000173941024000132/rlyb-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001739410-24-000132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer